Who are Diskus Fluticasone/salmeterol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Drug: Budesonide/formoterol (Symbicort Turbuhaler, Fluticasone/Salmeterol HFA, Fluticasone propionate/salmeterol combination, Budesonide/formoterol Turbuhaler, Fluticasone 250/salmeterol 25, Fluticasone 250/formoterol 10.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/diskus-fluticasone-salmeterol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Diskus Fluticasone/salmeterol — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Diskus Fluticasone/salmeterol (Diskus Fluticasone/salmeterol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inhaled corticosteroid/long-acting beta-2 agonist combination. Area: Respiratory/Pulmonology.

phase 3 Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol) Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Diskus Fluticasone/salmeterol (Diskus Fluticasone/salmeterol) — University Medical Center Groningen. Fluticasone/salmeterol is a combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and dilates airways to improve breathing.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Diskus Fluticasone/salmeterol TARGET	Diskus Fluticasone/salmeterol	University Medical Center Groningen	phase 3	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
Drug: Budesonide/formoterol (Symbicort Turbuhaler	Drug: Budesonide/formoterol (Symbicort Turbuhaler	AstraZeneca	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA)	Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (formoterol)
Fluticasone/Salmeterol HFA	Fluticasone/Salmeterol HFA	GlaxoSmithKline	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
Fluticasone propionate/salmeterol combination	Fluticasone propionate/salmeterol combination	GlaxoSmithKline	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
Budesonide/formoterol Turbuhaler	Budesonide/formoterol Turbuhaler	AstraZeneca	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor; beta-2 adrenergic receptor
Fluticasone 250/salmeterol 25	Fluticasone 250/salmeterol 25	Research in Real-Life Ltd	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
Fluticasone 250/formoterol 10	Fluticasone 250/formoterol 10	Research in Real-Life Ltd	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (formoterol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inhaled corticosteroid/long-acting beta-2 agonist combination class)

GlaxoSmithKline · 14 drugs in this class
Pearl Therapeutics, Inc. · 5 drugs in this class
AstraZeneca · 4 drugs in this class
Research in Real-Life Ltd · 3 drugs in this class
Chiesi Farmaceutici S.p.A. · 2 drugs in this class
Istituto per la Ricerca e l'Innovazione Biomedica · 1 drug in this class
Johns Hopkins University · 1 drug in this class
National Jewish Health · 1 drug in this class
SkyePharma AG · 1 drug in this class
University Medical Center Groningen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Diskus Fluticasone/salmeterol — Competitive Intelligence Brief. https://druglandscape.com/ci/diskus-fluticasone-salmeterol. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing